Dolasetron Injection and Goserelin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Dolasetron Injection
Goserelin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
Coadministration of goserelin with QT interval prolonging drugs cause additive effects on QT interval. Androgen deprivation caused by GnRH agonists/antagonists may prolong the QT interval. Consider whether the benefits of androgen deprivation therapy, like goserelin outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval3. Avoid concomitant use of goserelin with QT prolonging agents when possible. If coadministration is required, avoid use of drugs that cause electrolyte abnormalities (ie, hypokalemia or hypomagnesemia) 1, correct electrolyte abnormalities and consider periodic monitoring of ECGs and electrolytes 3.
Why it happens (mechanism)
Additive QT interval prolongation
Literature reports
1 report — tap to read
a) In a study evaluating male patients receiving androgen deprivation therapy (ADT) with individual case safety reports in the international pharmacovigilance database VigiBase, 184 cases of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% fatal cases), and 99 cases of sudden death associated with ADT were identified. Most cases of aLQTS/TdP (62%) and sudden death (88%) associated with ADT occurred without exposure to other drugs known to increase TdP risk; however exposure to 1 drug and 2 or more drugs at conditional, possible, or known TdP risk was reported in some aLQTS/TdP (23% or 43%) and sudden death (18% and 22%) events. Drugs considered as ADTs were abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism. Of the 10 ADTs evaluated, 7 had a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, including leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. Patients were a median of about 76 years, and the median onset to aLQTS/TdP events was 170 days (range, 7 to 4884 days) and sudden death events was 92 days (range, 0.25 to 4984 days). Patients were receiving ADT primarily to treat prostate cancer, with some receiving therapy for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%); 17% were receiving ADT combination therapy 2.
Common questions
Can I take Dolasetron Injection and Goserelin together?
Increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dolasetron Injection and Goserelin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Dolasetron Injection or Goserelin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
- Product Information: ZOLADEX® subcutaneous implant, goserelin subcutaneous implant. TerSera Therapeutics LLC, Deerfield, IL, 2026. DailyMed
Keep reading about Dolasetron Injection
Keep reading about Goserelin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist